Results 61 to 70 of about 315,867 (288)

Targeting neurotransmitter receptors for central nervous system therapeutics: from molecular signalling to behavioural pharmacology [PDF]

open access: yes, 2012
EThOS - Electronic Theses Online ServiceGBUnited ...
Newman-Tancredi, Adrian   +1 more
core   +1 more source

The diagnostic value of the circadian rhythm gene KLF10 in anxiety‐depressive disorders and its neuroimmune regulatory mechanisms

open access: yesAnimal Models and Experimental Medicine, EarlyView.
This graphical abstract illustrates the protective role and molecular mechanism of the circadian rhythm‐related gene KLF10, identified as a diagnostic biomarker and therapeutic target in anxiety‐depressive disorder. Model establishment and phenotypes: An anxiety‐depression model was successfully established by chronic restraint stress combined with ...
Anlan Liu   +4 more
wiley   +1 more source

Effect of the TAAR1 Partial Agonist Ralmitaront on Presynaptic Dopamine Synthesis Capacity Measured Using [F]DOPA PET in Naïve and Cocaine-Treated Mice

open access: yesMolecular Imaging
Purpose Elevated dopamine synthesis capacity is part of the pathophysiology of schizophrenia thought to underlie psychosis. Drugs that reduce this phenomenon could thus be potential treatments for these disorders.
David R. Bonsall PhD   +13 more
doaj   +1 more source

Cabergoline-induced mania in a patient of pituitary microadenoma

open access: yesIndian Journal of Psychological Medicine, 2017
Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation.
Satyakam Mohapatra, Mihir Ranjan Nayak
doaj   +1 more source

Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development

open access: yesAnnals of Neurology, EarlyView.
Objective Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...
Marlene Tahedl   +10 more
wiley   +1 more source

Dopamine induces optical changes in the cichlid fish lens. [PDF]

open access: yesPLoS ONE, 2010
The crystalline lens in the cichlid fish Aequidens pulcher undergoes a transformation of its optical properties every dawn and dusk as the eye adapts to changes in light conditions.
J Marcus Schartau   +2 more
doaj   +1 more source

Dopamine agonist–resistant prolactinomas

open access: yes, 2011
The authors' object in this paper was to review the definition, epidemiology, biology, resistance mechanisms, and treatment options for dopamine agonist–resistant prolactinomas (DARPs).
Michael C. Oh, Manish K. Aghi
core   +1 more source

Stimulus representation and the timing of reward-prediction errors in models of the dopamine system [PDF]

open access: yes, 2008
The phasic firing of dopamine neurons has been theorized to encode a reward-prediction error as formalized by the temporal-difference (TD) algorithm in reinforcement learning.
Sutton, Richard S.   +2 more
core   +1 more source

Enhancing Meat Quality Through Dietary Fiber: Insights Into the Gut Microbiota‐Derived Short‐Chain Fatty Acids‐Muscle Axis

open access: yesAnimal Research and One Health, EarlyView.
Dietary fiber (DF) modulates meat quality through the gut‐muscle axis by reshaping gut microbiota, improving intestinal integrity, reducing inflammation, and regulating muscle metabolism. These mechanisms influence muscle fiber characteristics and post‐mortem biochemistry, thereby enhancing tenderness, juiciness, color, flavor, and nutritional value of
Zeshan Zulfiqar   +8 more
wiley   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Home - About - Disclaimer - Privacy